Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 1891-1900 of 2400 for

Edit search filters
  1. Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN, Jacksonville, FL

  2. Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography

    Rochester, MN

  3. Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

    Rochester, MN

  4. Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer

    Rochester, MN

  5. Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM

    Rochester, MN

  7. Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

    Rochester, MN

  8. IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome

    Rochester, MN

  9. Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

    Jacksonville, FL

  10. Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer